Estrella Immunopharma Warrant
ESLAW
7 hedge funds and large institutions have $4.52M invested in Estrella Immunopharma Warrant in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASM
ATW SPAC Management
New York
|
+$80K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$80K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$59K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$35.9K |
| 5 |
D.E. Shaw & Co
New York
|
+$35.9K |
Top Sellers
ESLAW Hedge Fund Activity: Q3 2021 in Review
7 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma Warrant (ESLAW) for Q3 2021, worth a combined $4.52M.
Buyers outnumbered sellers: 7 funds opened new ESLAW positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was ATW SPAC Management, opening a new position worth an estimated $80K.
- 7 institutional investors held Estrella Immunopharma Warrant (ESLAW) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $4.52M of Estrella Immunopharma Warrant stock for Q3 2021.
- 7 funds opened new Estrella Immunopharma Warrant positions in Q3 2021 and 0 closed out, a net change of +7 holders.
- The largest Estrella Immunopharma Warrant buyer in Q3 2021 was ATW SPAC Management, an estimated $80K added.
Based on aggregated 13F filings for Q3 2021.